Clearmind Medicine Starts Patient Enrollment in Alcohol Use Disorder Trial
Ticker: CMND · Form: 6-K · Filed: Nov 25, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, drug-development, alcohol-use-disorder
TL;DR
Clearmind Medicine just kicked off patient enrollment at a new site for their alcohol use disorder trial. Big step forward!
AI Summary
Clearmind Medicine Inc. announced on November 25, 2025, that it has initiated patient enrollment at Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial targeting alcohol use disorder. This marks the activation of an additional clinical site for the trial, which is evaluating the efficacy and safety of their treatment.
Why It Matters
This milestone signifies progress in Clearmind's clinical development pipeline, potentially bringing a new treatment option for alcohol use disorder closer to market.
Risk Assessment
Risk Level: medium — Clinical trial progress is subject to regulatory approvals, patient recruitment, and trial outcomes, which carry inherent uncertainties.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- Tel Aviv Sourasky Medical Center (company) — Clinical trial site
- November 25, 2025 (date) — Announcement date
FAQ
What is the specific treatment being evaluated in the Phase I/IIa trial?
The filing does not specify the exact treatment being evaluated, only that it is for alcohol use disorder.
What is the primary objective of the Phase I/IIa trial?
The trial aims to evaluate the efficacy and safety of Clearmind's treatment for alcohol use disorder.
When was the press release announcing this enrollment officially filed?
The press release was incorporated into the Form 6-K filed on November 25, 2025.
What is Clearmind Medicine Inc.'s standard industrial classification?
Clearmind Medicine Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where is Clearmind Medicine Inc. headquartered?
Clearmind Medicine Inc. is located in Vancouver, British Columbia.
Filing Stats: 294 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2025-11-25 16:01:24
Filing Documents
- ea026711801-6k_clearmind.htm (6-K) — 11KB
- ea026711801ex99-1_clearmind.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-114724.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 25, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3